Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- SWITCHMRK 032 and 033 studies evaluated virologically suppressed patients stable on lopinavir/ritonavir-based antiretroviral therapy with ≥ 2 NRTIs who were switched to raltegravir or continued their original regimen[Eron 2010]
- Both studies were stopped prematurely because at Week 24 raltegravir failed to meet the protocol-defined criteria for noninferiority
- Both studies were stopped prematurely because at Week 24 raltegravir failed to meet the protocol-defined criteria for noninferiority
- SPIRAL study, which randomized patients suppressed on boosted-PI regimens to switch to raltegravir or continue their boosted PI, did not report an increased risk of virologic failure in the switch arm,[Martínez 2010] even in patients who had experienced previous virologic failure
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies